Rebeca Fernandes de Azevedo Dantas
Research Subjects
Rebeca Fernandes de Azevedo Dantas has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
Ana Clara Webe de Lima Moreira
1 shared publication- Arlley Cleverson Belo da Silva
Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil
1 shared publication - Bruna Galper
Universidade Estácio de Sá, Brazil
1 shared publication - Carolina Bantim Ciscotto
Universidade Estácio de Sá, Brazil
1 shared publication - Frederico Augusto Oliveira Teixeira
Universidade Federal de Mato Grosso do Sul
1 shared publication - Gabrielle Grecov Pissolatto
Pontifícia Universidade Católica
1 shared publication
Latest Publications
- 1 January 2022
- Published by Editora Creative
- p. 28-40
APRESENTAÇÃO CLÍNICA, TRATAMENTO E MANEJO DE EMERGÊNCIAS OBSTÉTRICAS POR ETIOLOGIA HIPERTENSIVA
- 1 January 2022
- Published by Editora Creative
- p. 28-40
APRESENTAÇÃO CLÍNICA, TRATAMENTO E MANEJO DE EMERGÊNCIAS OBSTÉTRICAS POR ETIOLOGIA HIPERTENSIVA
- Open Access
Integrative review on breast cancer screening in the transgender population: what do we know?
The lack of formal breast cancer screening guidelines for the transgender population and the unpreparedness of health professionals to provide adequate health care to this population are described in the literature. The objective of this integrative review was to present the proposals for breast cancer screening in the transgender population, based on the literature, being searched in the Medline, PubMed, SciELO, and Lilacs databases. The articles that addressed breast cancer screening in the female and/or male transgender population were selected, in addition to the associated studies with the use of hormone therapy and breast cancer in transgender people, using the terms such as “transgender people,” “early cancer diagnosis,” and “breast.” Of the 38 articles selected, 24 address recommendations for breast cancer screening in the female and/or male transgender population. There is limited population-based information on mammography screening in transgender people, which ultimately affects the analysis of cancer incidence in this population. The literature supports screening in the male transgender profile (similar to the female cisgender). In transgender females, recommendations are implemented based on expert’s opinions, such as mammographic screening after 5 years of hormone use. More studies on this subject are needed.
Open AccessIntegrative review on breast cancer screening in the transgender population: what do we know?
The lack of formal breast cancer screening guidelines for the transgender population and the unpreparedness of health professionals to provide adequate health care to this population are described in the literature. The objective of this integrative review was to present the proposals for breast cancer screening in the transgender population, based on the literature, being searched in the Medline, PubMed, SciELO, and Lilacs databases. The articles that addressed breast cancer screening in the female and/or male transgender population were selected, in addition to the associated studies with the use of hormone therapy and breast cancer in transgender people, using the terms such as “transgender people,” “early cancer diagnosis,” and “breast.” Of the 38 articles selected, 24 address recommendations for breast cancer screening in the female and/or male transgender population. There is limited population-based information on mammography screening in transgender people, which ultimately affects the analysis of cancer incidence in this population. The literature supports screening in the male transgender profile (similar to the female cisgender). In transgender females, recommendations are implemented based on expert’s opinions, such as mammographic screening after 5 years of hormone use. More studies on this subject are needed.
- Open Access
- 2 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (13)
Fetal hydropsia: challenges in etiologies
Introduction: Fetal hydrops is defined as the presence of abnormal fluid collections in two or more extravascular fetal compartments and body cavities. There are about 150 different underlying causes known today potentially leading to this fetal alteration. Objective: To analyze the etiologies involved in the occurrence of cases of fetal hydrops. Methods: A systematic literature review was carried out using the MedLine, Pubmed and Scielo databases, from 2015 to 2021, using the expressions: "fetal, hydrop, etiologies." Discussion: Fetal hydrops is divided into immune and non-immune. Immune results from anemia secondary to erythroblastosis by alloimmunization, so when there is maternal exposure to fetal antigens, it generates an immune response that results in the production of antibodies. History of blood transfusions, previous births, trauma and a history of alloimmunization are characterized as risk factors. Thus, immunoprophylaxis with anti-D immunoglobulin is indicated for all RhD negative pregnant women, with RhD positive male partner, with abundant fetal maternal hemorrhage during childbirth or events with potential sensitizer in the prenatal period. Conclusion: For an effective treatment, it is essential to identify the type of fetal hydrops in the patient and then the etiology of the disease, which is quite variable in Non-Immune Fetal Hydrops.
- 2 October 2021
- Published by Research, Society and Development in Research, Society and Development
- Vol. 10 (13)
Open AccessFetal hydropsia: challenges in etiologies
Introduction: Fetal hydrops is defined as the presence of abnormal fluid collections in two or more extravascular fetal compartments and body cavities. There are about 150 different underlying causes known today potentially leading to this fetal alteration. Objective: To analyze the etiologies involved in the occurrence of cases of fetal hydrops. Methods: A systematic literature review was carried out using the MedLine, Pubmed and Scielo databases, from 2015 to 2021, using the expressions: "fetal, hydrop, etiologies." Discussion: Fetal hydrops is divided into immune and non-immune. Immune results from anemia secondary to erythroblastosis by alloimmunization, so when there is maternal exposure to fetal antigens, it generates an immune response that results in the production of antibodies. History of blood transfusions, previous births, trauma and a history of alloimmunization are characterized as risk factors. Thus, immunoprophylaxis with anti-D immunoglobulin is indicated for all RhD negative pregnant women, with RhD positive male partner, with abundant fetal maternal hemorrhage during childbirth or events with potential sensitizer in the prenatal period. Conclusion: For an effective treatment, it is essential to identify the type of fetal hydrops in the patient and then the etiology of the disease, which is quite variable in Non-Immune Fetal Hydrops.